Document:

EX-10.30

 Exhibit 10.30 
 EMPLOYMENT AGREEMENT 
 THIS EMPLOYMENT AGREEMENT (this
“Agreement”) is made and entered into by and between MEDNAX SERVICES, INC., a Florida corporation (“Employer”) and DAVID A. CLARK (“Employee”) effective as the Effective Date. 

RECITALS 

WHEREAS, Employer is presently engaged in “Employer’s Business” as defined on Exhibit A hereto; and

 WHEREAS,    Employee has previously served in various management positions with the Employer,
it’s predecessor company and their affiliates, and was promoted to President, Mednax National Medical Group in January 2017; and 
 WHEREAS,    Employer and Employee previously entered in an Employment Agreement dated August 11, 2008, as amended (the “Prior Employment Agreement”), which will
be allowed to expire by its terms on August 10, 2018 and will not be renewed; and 

WHEREAS,    Employer desires to employ Employee and benefit from Employee’s contributions to Employer;
and 
 WHEREAS, in order to induce Employer to enter into this Agreement on the terms and conditions set forth herein
(including an increase in compensation over what was provided under the Prior Employment Agreement), and disclose its trade secrets and confidential information in connection with Employee’s employment by Employer and award from time to time
equity based compensation, Employee hereby agrees to be bound by the terms of this Agreement, including the arbitration, non-competition and related restrictive covenants set forth herein. 

NOW, THEREFORE, in consideration of the premises and mutual covenants set forth herein, the parties agree as follows: 

1.    Employment. 
 1.1.    Employment and Term. Employer hereby agrees to employ Employee and Employee hereby agrees to serve Employer on the terms and conditions set forth herein for an
“Initial Term” commencing February 12, 2018 (the “Effective Date”) and continuing for a period of three (3) years, unless sooner terminated as hereinafter set forth. Thereafter, the employment of Employee
hereunder shall automatically renew for successive one (1) year periods until terminated in accordance herewith. The Initial Term and any automatic renewals shall be referred to as the “Employment Period.” 

1.2.    Duties of Employee. During the Employment Period, Employee shall serve as President, Mednax National
Medical Group for Employer and perform such duties as are customary to the position Employee holds or as may be assigned to Employee from time to time by Employee’s 

 
supervisor (“Employee’s Supervisor”); provided, that such duties as assigned shall be customary to Employee’s role as an officer of Employer. Employee’s employment
shall be full-time and as such Employee agrees to devote substantially all of Employee’s attention and professional time to the business and affairs of Employer. Employee shall perform Employee’s duties honestly, diligently, competently,
in good faith and in the best interest of Employer. Employee will devote best efforts to the promotion of the goodwill of Employer and of its employees and affiliates. During the Employment Term, Employer shall promote the proficiency of Employee
by, among other things, providing Employee with Confidential Information, specialized professional development programs, and information regarding the organization, administration and operation of Employer. During the Employment Period, Employee
agrees that Employee will not, without the prior written consent of Employer (which consent shall not be unreasonably withheld), serve as a director on a corporate board of directors or in any other similar capacity for any institution other than
Employer. During the Employment Period, it shall not be a violation of this Agreement to (i) serve on civic or charitable boards or committees, or (ii) deliver lectures, fulfill speaking engagements or teach at educational institutions, so
long as such activities have been approved by Employer’s General Counsel and do not interfere with the performance of Employee’s responsibilities as an employee of Employer in accordance with this Agreement, including the restrictions of
Section 8 hereof. 
 1.3.    Place of Performance. Employee shall be based at Employer’s
offices located in Sunrise, Florida, except for required travel relating to Employer’s Business. 

2.    Base Salary and Performance Bonus. 

2.1.    Base Salary. Employee shall be paid an annual base salary as determined by Employee’s supervisor
from time to time (the “Base Salary”), payable in installments consistent with Employer’s customary payroll schedule and subject to applicable withholding for taxes and other Employee directed withholdings. Any increase to
Employee’s Base Salary that is approved by Employee’s Supervisor shall become Employee’s new Base Salary for purposes of this Agreement. 
 2.2.    Performance Bonus. Employee shall be eligible for an annual bonus of up to the amount set forth on Exhibit B (the “Performance Bonus”). The amount of the
actual bonus paid to Employee, if any, shall be based upon the achievement of specific objectives to be developed and agreed upon by Employee and Employee’s Supervisor each year and the performance of Employer. Except in the situations
described in Sections 5.2, 5.3, 5.4, 5.5 and 5.7, the Performance Bonus shall only be payable to Employee if Employee is employed with Employer as of the date that the Performance Bonus is paid by Employer. Each Performance Bonus shall be paid in
the calendar year immediately following the calendar year in which it is earned, as soon as practicable after the audited financial statements for Employer for the year for which the bonus is earned have been released; provided, however, that if
calculation of Employee’s Performance Bonus is not administratively practicable due to events beyond the control of Employer, then Employer may delay payment of the Performance Bonus provided that the payment is made during the first taxable
year of Employee in which the calculation of the amount of the payment is administratively practicable. 

  
 2 

 3.    Benefits. 

3.1.    Expense Reimbursement. Employer shall promptly reimburse Employee for all out-of-pocket expenses reasonably incurred by Employee during the Employment Period on behalf of or in connection with Employer’s Business pursuant to the reimbursement
standards and guidelines of Employer in effect from time to time. Employee shall account for such expenses and submit reasonable supporting documentation to Employer in accordance with Employer’s policies in effect from time to time.

 3.2    Employee Benefits. During the Employment Period, Employee shall be entitled to participate
in such health, welfare, disability, retirement savings and other fringe benefit plans and programs (subject to the terms and conditions of such plans and programs) as may be provided from time to time to employees of Employer and to the extent that
such plans and programs are applicable to other similarly situated employees of Employer. 

3.3.    Leave Time. During the Employment Period, Employee shall be entitled to paid vacation and leave days
each calendar year in accordance with the leave policies established by Employer from time to time, but in no event less than thirty-eight (38) days per year. Any leave time not used during each fiscal year of Employer may be carried over into
the next year to the extent permitted by Employer policy. 
 3.4    Equity Plans. During the
Employment Period, Employee shall be eligible to participate in MEDNAX, Inc.‘s Amended and Restated 2008 Incentive Compensation Plan, as amended, or any other similar plan adopted by MEDNAX, Inc. (each an “Equity Plan”) that provides
for the issuance of stock options, stock appreciation rights, restricted stock, deferred stock, bonus stock, awards payable in stock or any other stock based award (each an “Equity Award”). Employee’s stock-based award each year shall
be determined by the Compensation Committee of MEDNAX, Inc.’s Board of Directors based on Employee’s performance and Employer’s performance during the immediately preceding year and shall be at least consistent with the Compensation
Committee’s determination of Employee’s stock-based award in prior years. Every Equity Award made to Employee shall be subject to the terms and conditions of this Agreement, the applicable award agreement and the terms of the Equity Plan.
Employee shall also be eligible to participate in MEDNAX, Inc.’s non-qualified employee stock purchase plan and any successor plan. Employee acknowledges Employee’s participation in the Equity Plan
pursuant to this Section 3 is sufficient consideration for Employee to enter into this Agreement, including the restrictive covenants set forth in Section 8 below.  

4.    Termination. 
 4.1.    Termination for Cause. Employer may terminate Employee’s employment under this Agreement for Cause. As used in this Agreement, the term “Cause” shall
mean: 
 (a)    Any act or omission of Employee, which is materially contrary to the business
interests, reputation or goodwill of Employer; 
 (b)    A material breach by Employee of
Employee’s obligations under this Agreement, which breach is not promptly remedied upon written notice from Employer; 

  
 3 

 (c)    Employee’s refusal to perform
Employee’s duties as assigned pursuant to this Agreement other than a refusal which is remedied by Employee promptly after receipt of written notice thereof by Employer; or 

(d)    Employee’s failure or refusal to comply with a reasonable policy, standard or regulation
of Employer in any material respect, including but not limited to Employer’s sexual harassment, other unlawful harassment, workplace discrimination or substance abuse policies. 
 The termination date for a termination of Employee’s employment under this Agreement pursuant to this Section 4.1 shall be the date specified by Employer in a written notice to Employee of
finding of Cause, which may not be retroactive. Upon any termination of Employee’s employment under this Agreement pursuant to this Section 4.1, Employee shall be entitled to the compensation specified in Section 5.1 hereof.

 4.2.    Disability. Employer may terminate Employee’s employment under this Agreement upon
the Disability (as defined below) of Employee. Subject to the requirements of applicable law, Employee shall be deemed to have a “Disability” for purposes of this Agreement in the event of (i) Employee’s inability to perform
Employee’s duties hereunder, with or without a reasonable accommodation, as a result of physical or mental illness or injury, and (ii) a determination by an independent qualified physician selected by Employer and acceptable to Employee
(which acceptance shall not be unreasonably withheld) that Employee is currently unable to perform such duties and in all reasonable likelihood such inability will continue for a period in excess of an additional ninety (90) or more days in any
one hundred twenty (120) day period. The termination date for a termination of this Agreement pursuant to this Section 4.2 shall be the date specified by Employer in a notice to Employee, which date shall not be retroactive. Upon any
termination of this Agreement pursuant to this Section 4.2, Employee shall be entitled to compensation and/or benefits in accordance with, and subject to, the provisions of Section 5.2 hereof. 

4.3.    Death. Employee’s employment under this Agreement shall terminate automatically upon the death of
Employee, without any requirement of notice by Employer to Employee’s estate. The date of Employee’s death shall be the termination date for a termination of Employee’s employment under this Agreement pursuant to this
Section 4.3. Upon any termination of Employee’s employment under this Agreement pursuant to this Section 4.3, Employee shall be entitled to the compensation specified in Section 5.3 hereof. 

4.4.    Termination by Employer Without Cause. Employer may terminate Employee’s employment without cause
by giving Employee written notice of such termination. The termination date shall be the date specified by Employer in such notice, which may be up to ninety (90) days from the date of such notice. Upon any termination of Employee’s
employment under this Agreement pursuant to this Section 4.4, Employee shall be entitled to compensation and/or benefits in accordance with, and subject to, the provisions of Section 5.4 hereof. 

  
 4 

 4.5.    Termination by Employee Due to Poor Health. Employee may
terminate Employee’s employment under this Agreement upon written notice to Employer if Employee’s health should become impaired to any extent that makes the continued performance of Employee’s duties under this Agreement hazardous to
Employee’s physical or mental health or Employee’s life (regardless of whether such condition would be deemed a Disability under any other Section of this Agreement), provided that Employee shall have furnished Employer with a
written statement from a qualified doctor to that effect, and provided further that, at Employer’s written request and expense, Employee shall submit to a medical examination by an independent qualified physician selected by Employer and
acceptable to Employee (which acceptance shall not be unreasonably withheld), which doctor shall substantially concur with the conclusions of Employee’s doctor. The termination date shall be the date specified in Employee’s notice to
Employer, which date may not be earlier than thirty (30) days nor later than ninety (90) days from Employer’s receipt of such notice. Upon any termination of Employee’s employment under this Agreement pursuant to this
Section 4.5, Employee shall be entitled to compensation and/or benefits in accordance with, and subject to, the provisions of Section 5.5 hereof. 
 4.6.    Termination by Employee. Employee may terminate Employee’s employment under this Agreement for any reason whatsoever upon not less than ninety (90) days prior
written notice to Employer. Upon receipt of such notice from Employee, Employer may, at its option, require Employee to terminate employment at any time in advance of the expiration of such ninety (90) day period. The termination date under
this Section 4.6 shall be the date specified by Employer, but in no event more than ninety (90) days after Employer’s receipt of notice from Employee as contemplated by this Section. Upon any termination of Employee’s employment
under this Agreement pursuant to this Section 4.6, Employee shall be entitled to compensation and/or benefits in accordance with, and subject to, the provisions of Section 5.6 hereof. 

4.7.    Termination by Employee for Good Reason. Employee may terminate Employee’s employment hereunder
for Good Reason. For purposes of this Section, “Good Reason” shall mean: 
 (a)
    a decrease in Employee’s Base Salary; 
 (b)     a decrease in
the Performance Bonus potential utilized by Employer in determining a Performance Bonus for Employee; or 

(c)    within a twenty-four (24) month period after a Change in Control (as defined below),
Employee is either (i) assigned any position, duties, responsibilities or compensation that is inconsistent with the position, duties, responsibilities or compensation of Employee prior to such Change in Control, (ii) required to report to
any person other than the President or Chief Executive Officer of Employer in place just prior to the Change in Control (unless Employee becomes Chief Executive Officer of Employer or its equivalent and reports directly to the Board, as defined
below), or (iii) required to perform services under this Agreement from another location more than twenty-five (25) miles from Employee’s location prior to the Change in Control. For purposes of this Agreement, “Change in
Control” shall mean (i) the acquisition by a person or an entity or a group of persons and entities, directly or indirectly, of more than fifty (50%) percent of MEDNAX, Inc.’s common

  
 5 

 
stock in a single transaction or a series of transactions (hereinafter referred to as a “50% Change in Control”), (ii) a merger or other form of corporate reorganization of MEDNAX, Inc.
resulting in an actual or de facto 50% Change in Control, or (iii) the failure of Applicable Directors (defined below) to constitute a majority of MEDNAX, Inc.’s Board of Directors (the “Board”) during any two
(2) consecutive year period after the date of this Agreement (the “Two-Year Period”). “Applicable Directors” shall mean those individuals who are members of the Board at the inception
of a Two-Year Period and any new director whose election to the Board or nomination for election to the Board was approved (prior to any vote thereon by the shareholders) by a vote of at least two-thirds (2/3) of the directors then still in office who either were directors at the beginning of the Two-Year Period at issue or whose election or nomination for election
during such Two-Year Period was previously approved as provided in this sentence; or 
 (d)    the assignment to Employee of any position inconsistent with the present position Employee holds, or material diminution in Employee’s authority, excluding for this purpose
any isolated, insubstantial and inadvertent action not taken in bad faith and which is remedied by Employer promptly after receipt of written notice; or 
 (e)    the requirement by Employer that Employee be based in any office or location outside of the metropolitan area where Employer’s present corporate offices are located (it
being understood that Employee may be presently based at another location), except for travel reasonably required in the performance of Employee’s duties. 
 (f)    any other action or inaction that constitutes a material breach of this Agreement by Employer. 
 If Employee desires to terminate Employee’s employment under this Agreement pursuant to this Section, Employee must, within ninety (90) days after the occurrence of events giving rise to the
Good Reason, provide Employer with a written notice describing the Good Reason in reasonable detail. If Employer fails to cure the matter cited within thirty (30) days after the date of Employee’s notice, then this Agreement shall
terminate as of the end of such thirty (30) day cure period, provided, however, that Employer may, at its option, require Employee to terminate employment at any time in advance of the expiration of such thirty (30) day cure period.
If Employee terminates Employee’s employment under this Agreement pursuant to this Section 4.7, then Employee shall be entitled to compensation and/or benefits in accordance with, and subject to, the provisions of Section 5.7 hereof.

 5.    Compensation and Benefits Upon Termination. 

5.1.    Cause. If Employee’s employment is terminated for Cause, Employer shall pay Employee’s Base
Salary through the termination date specified in Section 4.1 at the rate in effect at the termination date. Upon payment of such amounts, plus any amounts as may be due under Section 5.8 below, Employer shall have no further obligation to
Employee under this Agreement. 

  
 6 

 5.2.    Disability.    In the event of
Employee’s Disability, Employee shall continue to receive Employee’s Base Salary for the first ninety (90) days of Disability. Thereafter, payments, if any, shall be administered pursuant to Employer’s sponsored long-term
disability policy. If Employee’s employment is terminated pursuant to Section 4.2 in connection with Employee’s Disability, Employee shall receive fifty percent (50%) of Employee’s annual Base Salary at the rate in effect at the
termination date, payable in six (6) equal monthly installments after the termination date, plus a bonus calculated in accordance with Section 5.11 and any amounts as may be due under Section 5.8 and 5.9. 

5.3.    Death. Upon Employee’s death during the Employment Period, Employer shall pay to the person or
entity designated by Employee in a notice filed with Employer or, if no person is designated, to Employee’s estate any unpaid amounts of Base Salary to the date of Employee’s death, plus any amounts as may be due under Sections 5.8 and
5.11 below. Any payments Employee’s spouse, beneficiaries or estate may be entitled to receive pursuant to any pension plan, employee welfare benefit plan, life insurance policy, or similar plan or policy then maintained by Employer shall be
determined and paid in accordance with the written instruments governing the respective plans and policies. In the event of Employee’s death during the Employment Period, Employer shall notify Employee’s designee or estate of the Equity
Awards held by Employee and the procedures pursuant to which all vested stock options may be exercised and other Equity Awards may be realized under the terms applicable to such awards. Upon full payment of all amounts required to be paid under this
Section 5.3, Employer shall have no further obligation under this Agreement. 

5.4.    Termination by Employer Without Cause. If Employer terminates Employee’s
employment in accordance with Section 4.4, then (i) Employer shall pay Employee’s Base Salary through the termination date specified in Section 4.4 at the rate in effect at such termination date, plus any amount due under
Section 5.8 hereof; (ii) within thirty (30) days, pay Employee a bonus calculated in accordance with Section 5.11 hereof; (iii) Employer shall continue to pay Employee’s monthly Base Salary for a period of eighteen
(18) months after the termination date; (iv) within thirty (30) days of the first (1st) anniversary of the termination date, pay Employee an amount equal to Employee’s Average Annual Performance Bonus (as defined below); and (v) if applicable, Employee shall vest into the
Accelerated Awards (as defined below) as set forth in Section 5.14 hereof. For purposes of this Agreement, “Average Annual Performance Bonus” shall be equal to the average of the percentage of the Performance Bonus target achieved by
Employee for the three (3) full calendar years prior to the termination date, and calculated based on Employee’s Base Salary and target Performance Bonus in Employee’s current position. For illustration purposes, if Employee earned
40%, 100% and 70% of Employee’s target Performance Bonus in each of the three full calendar years prior to termination, and Employee’s current target Performance Bonus was 100% of Base Salary, and Base Salary was $450,000.00, then
Employee’s Average Annual Performance Bonus would equal $315,000.00. ((40%+ 100% + 70%) / 3 x 100% x $450,000.00 = $315,000.00). Upon payment of the amounts specified under Sections 5.4 and 5.11, Employer shall have no further obligation
under this Agreement. 
 5.5.    Termination by Employee Due to Poor Health. If Employee terminates
Employee’s employment under this Agreement pursuant to Section 4.5 hereof, Employer shall pay to Employee any unpaid amounts of Base Salary to the termination date specified in Section 4.5, plus any disability payments otherwise
payable by or pursuant to plans provided by Employer, plus any amounts as may be due under Section 5.8 and 5.11 below. 

  
 7 

 5.6.    Termination by Employee. If Employee’s employment
under this Agreement terminates pursuant to Section 4.6 hereof, Employer shall pay to Employee any unpaid amounts of Base Salary to the termination date specified in Section 4.6, plus any amounts as may be due under Section 5.8 below.
In the event that the termination date specified by Employer is less than ninety (90) days after the date of Employer’s receipt of notice as contemplated by Section 4.6, then Employer shall continue Employee’s Base Salary for a
period of days equal to ninety (90) minus the number of days from Employee’s notice to the termination date. 

5.7.    Termination for Good Reason. If Employee’s employment under this Agreement is terminated
pursuant to Sections 4.7(a), (b), (d), (e), or (f), then Employer shall (i) pay Employee’s Base Salary through the termination date specified in Section 4.7 at the rate in effect at such termination date, (ii) pay any
amounts as may be due under Section 5.8 and 5.11, and (iii) continue to pay Employee’s Base Salary for a period of twelve (12) months after the termination date. If this Agreement is terminated pursuant to Section 4.7(c),
then Employer shall (i) pay Employee’s Base Salary through the termination date specified in Section 4.7 at the rate in effect at such termination date, (ii) pay any amounts as may be due under Sections 5.8 and 5.11, and
(iii) continue to pay Employee’s Base Salary for a period of eighteen (18) months after the termination date. In addition, notwithstanding any contrary provision in any Equity Plan, in the event of Employee’s termination
pursuant to Section 4.7(c), any unvested Equity Awards held by Employee on the termination date shall fully vest and in the case of stock options, become immediately exercisable. 

5.8.    Expense Reimbursement. Employee shall be entitled to reimbursement for reasonable business expenses
incurred prior to the termination date, subject, however to the provisions of Section 3.1. Such reimbursement shall be made at the times and in accordance with Employer’s normal procedures for reimbursements. 

5.9.    Continuation of Benefit Plans. Employee shall be entitled to continuation of health, medical,
hospitalization and other similar health insurance programs on the same basis as regular, full-time employees of Employer and their eligible dependents during the period that Employee is receiving Base Salary payments under Section 5 of this
Agreement and, in all cases, as provided by any applicable law. Following such period of continued benefit plan coverage, Employee and each of his eligible dependents shall be entitled to elect for continuation of coverage provided pursuant to
Section 601 et. seq. of the Employee Retirement Income Security Act of 1974, 29 USC §1101 (“COBRA”). 

5.10    Period for Exercising Stock Options After Termination. Except as to incentive stock options granted in
accordance with Section 422 of the Internal Revenue Code, after termination of Employee’s employment under this Agreement for any reason other than pursuant to Section 4.1, Employee shall be allowed a period of one hundred eighty
(180) days during which to exercise any vested options to purchase MEDNAX, Inc.’s common stock or vested stock appreciation rights and realize any other vested Equity Awards that may be granted or made under any Equity Plan; provided,
however, that in no event shall the period during which Employee may exercise any vested stock option or vested stock appreciation right be extended pursuant to this Section 5.10 to a date that is later than the earlier of (i) the latest
date upon which the stock right 

  
 8 

 
could have expired by its original terms under any circumstances or (ii) the tenth (10th) anniversary of the original date of grant of the stock right. In all other respects, the terms of the applicable
Equity Plan shall control the terms and conditions of any Equity Awards. 
 5.11.    Performance Bonus.
In the situations described in Sections 5.2, 5.3, 5.4, 5.5 and 5.7, upon termination of this Agreement, Employee will be paid, solely in consideration of services rendered by Employee prior to termination, a bonus with respect to
Employer’s fiscal year in which the termination date occurs, equal to the Performance Bonus, if any, that would have been payable to Employee, based on Employee and Employer meeting certain goals and objectives, for the fiscal year if
Employee’s employment had not been terminated, multiplied by the number of days in the fiscal year prior to and including the date of termination and divided by three hundred sixty five (365). The amount of the Post-Termination Performance
Bonus paid in the situations described in Sections 5.2, 5.3, 5.4 5.5 and 5.7 shall be determined in good faith by Employer in its sole discretion at the time that Employer distributes bonuses to similarly situated employees. Any amount payable under
this Section 5.11 shall be paid to Employee when Employer pays performance bonuses to its eligible employees, which shall be in the calendar year following the termination date of this Agreement. In addition, in the situations described in
Section 5.7, Employee will be paid, solely in consideration of services rendered by Employee prior to termination, an additional bonus with respect to Employer’s fiscal year in which the termination date occurs, equal to the greater of
Employee’s Average Annual Performance Bonus (as defined in Section 5.4) or Employee’s bonus for the year immediately preceding Employee’s termination. Such additional bonus shall be payable to Employee within ninety
(90) days of Employee’s termination date pursuant to Section 4.7. 

5.12.    Section 409A Compliance. 

(a)    General. It is the intention of both Employer and Employee that the benefits and rights
to which Employee could be entitled in connection with termination of employment comply with Section 409A of the Code and the Treasury Regulations and other guidance promulgated or issued thereunder (“Section 409A”), and the
provisions of this Agreement shall be construed in a manner consistent with that intention. If Employee or Employer believes, at any time, that any such benefit or right does not so comply, it shall promptly advise the other and shall negotiate
reasonably and in good faith to amend the terms of such benefits and rights such that they comply with Section 409A of the Code (with the most limited possible economic effect on Employee and on Employer). 

(b)    Distributions on Account of Separation from Service. If and to the extent required to
comply with Section 409A, no payment or benefit required to be paid under this Agreement on account of termination of Employee’s employment shall be made unless and until Employee incurs a “separation from service”, within the
meaning of Section 409A. 
 (c)    6 Month Delay for Specified Employees. 

(i)    If Employee is a “specified employee”, then no payment or benefit that is payable on account of
Employee’s “separation from service”, as that term is defined for purposes of Section 409A, shall be made before the date that is six months after Employee’s “separation from service” (or, if earlier, the date of
Employee’s death) if 

  
 9 

 
and to the extent that such payment or benefit constitutes deferred compensation (or may be nonqualified deferred compensation) under Section 409A and such deferral is required to comply
with the requirements of Section 409A. Any payment or benefit delayed by reason of the prior sentence shall be paid out or provided in a single lump sum at the end of such required delay period in order to catch up to the original payment
schedule. 
 (ii)    For purposes of this provision, Employee shall be considered to be a
“specified employee” if, at the time of his or her separation from service, Employee is a “key employee”, within the meaning of Section 416(i) of the Code, of Employer (or any person or entity with whom Employer would be
considered a single employer under Section 414(b) or Section 414(c) of the Code) any stock in which is publicly traded on an established securities market or otherwise. 

(iii)    Unless otherwise required to comply with Section 409A, a payment or benefit shall not be
deferred pursuant to this provision if: 
 (x)    it is not made on
account of Employee’s “separation from service”, (y) it is required to be paid no later than within 2 1/2 months after the end of the taxable year of Employee in which the payment or benefit is no longer subject to
a “substantial risk of forfeiture”, as that term is defined for purposes of Section 409A, or (z) the payment satisfies the following requirements: (A) it is being paid or provided due to Employer’s termination of
Employee’s employment without Cause (Section 4.4) or Employee’s termination of employment after a Change in Control for the reasons set forth in Section 4.7 hereof, (B) it does not exceed two times the lesser of
(1) Employee’s annualized compensation from Employer for the calendar year prior to the calendar year in which the termination of Employee’s employment occurs, and (2) the maximum amount of compensation that may be taken into
account under a qualified plan pursuant to Section 401(a)(17) of the Code for the year in which Employee’s employment terminates, and (C) the payment is required under this Agreement to be paid no later than the last day of the second
calendar year following the calendar year in which Employee incurs a “separation from service”. 

(d)    No Acceleration of Payments. Neither Employer nor Employee, individually or in combination, may
accelerate any payment or benefit that is subject to Section 409A, except in compliance with Section 409A and the provisions of this Agreement, and no amount shall be paid prior to the earliest date on which it may be paid without
violating Section 409A. 
 (e)    Treatment of Each Installment as a Separate Payment.
For purposes of applying the provisions of Section 409A to this Agreement, each separately identified amount to which Employee is entitled under this Agreement shall be treated as a separate payment. In addition, to the extent permissible under
Section 409A, any series of installment payments under this Agreement shall be treated as a right to a series of separate payments. 

  
 10 

 (f)    Reimbursements and
In-Kind Benefits. 
 (i)    Any reimbursements by
Employer to Employee of any eligible expenses pursuant to Section 3.1 or 5.8 of this Agreement, that are not excludible from Employee’s income for Federal income tax purposes (“Taxable Reimbursements”) shall be made on or before
the last day of the taxable year of Employee following the year in which the expense was incurred. 

(ii)    The amount of any Taxable Reimbursements, and the value of any
in-kind benefits to be provided to Employee under this Agreement, during any taxable year of Employee shall not affect the expenses eligible for reimbursement, or
in-kind benefits to be provided, in any other taxable year of Employee. 

(iii)    The right to Taxable Reimbursements, or in-kind
benefits, shall not be subject to liquidation or exchange for another benefit. 
 5.13.    Release.
Employer shall provide Employee with a general release in the form attached as Exhibit C (subject to such modifications as Employer may reasonably request) within seven (7) days after Employee’s termination date. Payments or
benefits to which Employee may be entitled pursuant to this Section 5 (other than any accrued but unpaid Base Salary and employee benefits as of the end of the Employment Period) (the “Severance Amounts”) shall be conditioned upon
Employee executing the general release within 21 days after receiving it from Employer and the general release becoming irrevocable upon the expiration of 7 days following the Employee’s execution of it. Payment of the Severance Amounts shall
be suspended during the period (the “Suspension Period”) that begins on Employee’s termination date and ends on the date (“Suspension Termination Date”) that is thirty-five (35) days after Employee’s termination
date; provided, however, that this suspension shall not apply, and Employer shall be required to provide, any continued health insurance coverage that would be required under Section 5.9 hereof during the Suspension Period. If Employee executes
the general release and the general release becomes irrevocable by no later than the Suspension Termination Date, then payment of any Severance Amounts that were suspended pursuant to this provision shall be made in the first payroll period that
follows the Suspension Termination Date, and any Severance Amounts that are payable after the Suspension Termination Date shall be paid at the times provided in Section 5. 

5.14.    Vesting of Incentive Awards. Notwithstanding any contrary provision in this Agreement or any
Equity Plan then maintained by MEDNAX, Inc.: 
 (a) all Equity Awards granted to Employee by MEDNAX, Inc. prior to termination
of this Agreement shall continue to vest until fully vested following a termination of Employee’s employment pursuant to Section 4.2, 4.3, and 4.5; and 
 (b) in the event of a Change in Control after the date of this Agreement: 
 (i)    if, prior to the one (1) year anniversary of the effective date of such Change in Control, the employment by MEDNAX, Inc. or its affiliates or successors of both Roger J.
Medel, M.D. and Joseph M. Calabro is terminated for any reason, or 

  
 11 

 
they both no longer hold the positions they held just prior to the Change in Control (and neither holds the top executive position in the company), then the Equity Awards granted to the Employee
that are outstanding (the “Accelerated Awards”) shall become fully vested and payable to the Employee on the first anniversary of the effective date of such Change in Control; provided, however, that any portion of the Accelerated Awards
that is scheduled to become vested and payable pursuant to its terms prior to the first anniversary of such Change in Control shall become vested and payable to the Employee pursuant to its terms; and 

(ii)     if, after the one (1) year anniversary of the effective date of such Change in Control,
the employment by MEDNAX, Inc. or its affiliates or successors of both Roger J. Medel, M.D. and Joseph M. Calabro is terminated for any reason, or they both no longer hold the positions they held just prior to the Change in Control (provided that
neither holds the top executive position in the company), then the Accelerated Awards shall become fully vested and payable to the Employee on the one (1) year anniversary of the termination date, or date of the change in position of Roger J.
Medel, M.D. or Joseph M. Calabro, whichever termination date or date in change of position is later; provided, however, that any portion of the Accelerated Awards that is scheduled to become vested and payable pursuant to its terms prior to the one
(1) year anniversary of such termination date or date of change in position shall become vested and payable to the Employee pursuant to its terms; 
 provided in the case of both clauses (i) and (ii) above, that the Employee remains in Continuous Service (as defined in the applicable Equity Plan) from the date of this Agreement through the date on
which such Accelerated Awards would vest pursuant to clauses (i) or (ii) above, as applicable. 

(iii)    if at any time after a Change in Control after the date of this Agreement, Employee’s employment is
terminated pursuant to Section 4.4 or 4.7(a),(b)(d) (e) or (f), then all of the Accelerated Awards will be fully vested and exercisable as of the effective date of such termination. 

Notwithstanding anything to the contrary in this Agreement, the Equity Plans or the Equity Awards, in the event of a Change in Control
immediately following which neither the common stock of MEDNAX, Inc. nor the common equity of its successor, parent or subsidiary is listed for trading on a national securities exchange (a “Going Private Transaction”), then all unvested
Equity Awards granted to the Employee shall be adjusted so that in lieu of the Employee’s right to receive shares of common stock of MEDNAX, Inc. pursuant to the terms of such Equity Awards, the Employee shall be entitled to receive, for each
share of common stock of MEDNAX, Inc. that Employee would otherwise be entitled to receive pursuant to such Equity Awards, an amount of cash equal to the amount per share of common stock of MEDNAX, Inc. paid to the shareholders of MEDNAX, Inc. in
such Going Private Transaction, as determined by the Compensation Committee of the Board in its sole discretion, in each case consistent with the vesting schedule of such Equity Awards and shall remain subject to the acceleration provisions set
forth in this Section 5.14. 

  
 12 

 6.    Successors; Binding Agreement. 

6.1.    Successors. Employer shall require any successor (whether direct or indirect, by purchase, merger,
consolidation or otherwise) acquiring a majority of Employer’s voting common stock or any other successor to all or substantially all of the business and/or assets of Employer to expressly assume and agree to perform this Agreement in the same
manner and to the same extent that Employer would be required to perform it if no such succession had taken place and Employee hereby consents to any such assignment. In such event, “Employer” shall mean Employer as previously defined and
any successor to its business and/or assets which executes and delivers the agreement provided for in this Section 6 or which otherwise becomes bound by all the terms and provisions of this Agreement by operation of law. This Section shall not
limit Employee’s ability to terminate this Agreement in the circumstances described in Section 4.7 in the event of a Change in Control. 
 6.2.    Benefit. This Agreement and all rights of Employee under this Agreement shall inure to the benefit of and be enforceable by Employee’s personal or legal
representatives, executors, administrators, successors, heirs, distributees, devisees and legatees. If Employee should die after the termination date and amounts would have been payable to Employee under this Agreement if Employee had continued to
live, including under Section 5 hereof, then such amounts shall be paid to Employee’s devisee, legatee, or other designee or, if there is no such designee, Employee’s estate. 

7.    Conflicts with Prior Employment Contract. Except as otherwise provided in this Agreement with
respect to the August 11, 2018 expiration of the Prior Employment Agreement, this Agreement constitutes the entire agreement among the parties pertaining to the subject matter hereof, and supersedes and revokes any and all prior or existing
agreements, written or oral, relating to the subject matter hereof, and this Agreement shall be solely determinative of the subject matter hereof. 
 8.    Restrictive Covenants; Confidential Information; Work Product; Injunctive Relief. 
 8.1.    No Material Competition. Employer and Employee acknowledge and agree that a strong relationship and connection exists between Employer and its current and prospective
patients, referral sources, and customers as well as the hospitals and healthcare facilities at which it provides professional services. Employer and Employee further acknowledge and agree that the restrictive covenants described in this Section are
designed to enforce, and are ancillary to or part of, the promises contained in this Agreement and are reasonably necessary to protect the legitimate interests of Employer in the following: (1) the use and disclosure of the Confidential
Information as described in Section 8.4; (2) the professional development activities described in Section 1.2; and (3) the goodwill of the Employer, as promoted by Employee as provided in Section 1.2. The foregoing listing is by
way of example only and shall not be construed to be an exclusive or exhaustive list of such interests. Employee acknowledges that the restrictive covenants set forth below are of significant value to Employer and were a material inducement to
Employer in agreeing to the terms of this Agreement. Employee further acknowledges that the goodwill and other proprietary interest of Employer will suffer irreparable and continuing damage in the event Employee enters into competition with Employer
in violation of this Section. 

  
 13 

 Therefore, Employee agrees that, except with respect to services performed under this Agreement on behalf of
Employer, Employee shall not, at any time during the Restricted Period (as defined below), for Employee or on behalf of any other person, persons, firm, partnership, corporation or employer, participate or engage in or own an interest in,
directly or indirectly, any individual proprietorship, partnership, corporation, joint venture, trust or other form of business entity, whether as an individual proprietor, partner, joint venturer, officer, director, member, employee, consultant,
independent contractor, stockholder, lender, landlord, finder, agent, broker, trustee, or in any manner whatsoever, if such entity or its affiliates is engaged in, directly or indirectly, “Employer’s Business,” as defined on Exhibit A
hereto. Employee acknowledges that, as of the date hereof, Employee’s responsibilities will include matters affecting the businesses of Employer listed on Exhibit A. For purposes of this Section 8, the “Restricted Period” shall
mean the Employment Period plus (i) eighteen (18) months in the event this Agreement is terminated pursuant to Sections 4.1, 4.7(a), 4.7(b), 4.7(d), 4.7(e), or 4.7(f) or (ii) twenty-four (24) months in the event the Agreement is
terminated for any other reason. 
 8.2.    No Hire. Employee further agrees that Employee shall
not, at any time during the Employment Period and for a period of eighteen (18) months immediately following termination of this Agreement for any reason, for Employee or on behalf of any other person, persons, firm, partnership,
corporation or employer, employ, or knowingly permit any company or business directly or indirectly controlled by Employee to employ or otherwise engage (a) any person who is a then current employee or independent contractor of Employer or one
of its affiliates, or (b) any person who was an employee or independent contractor of Employer or one of its affiliates in the prior six (6) month period, or in any manner seek to induce such persons to leave his or her employment or
engagement with Employer or one of its affiliates (including without limitation for or on behalf of a subsequent employer of Employee). 
 8.3     Non-solicitation. Employee further agrees that Employee shall not, at any time during the Employment Period and for a
period of eighteen (18) months immediately following termination of this Agreement for any reason, for Employee or on behalf of any other person, persons, firm, partnership, corporation or employer, solicit or accept business from or take any
action that would interfere with, diminish or impair the valuable relationships that Employer or its affiliates have with (i) hospitals or other health care facilities with which Employer or its affiliates have contracts to render professional
services or otherwise have established relationships, (ii) patients, (iii) referral sources, (iv) vendors, (v) any other clients of Employer or its affiliates, or (vi) prospective hospitals, patients, referral sources, vendors or
clients whose business Employee was aware that Employer or any affiliate of Employer was in the process of soliciting at the time of Employee’s termination (including potential acquisition targets). 

8.4.    Confidential Information. At all times during the term of this Agreement, Employer shall provide
Employee with access to “Confidential Information.” As used in this Agreement, the term “Confidential Information” means any and all confidential, proprietary or trade secret information, whether disclosed, directly or
indirectly, verbally, in writing or by any other means in tangible or intangible form, including that which is conceived or developed by Employee, applicable to or in any way related to: (i) patients with whom Employer has a physician/patient
relationship; (ii) the present or future business of Employer; or (iii) the research and development of 

  
 14 

 
Employer. Without limiting the generality of the foregoing, Confidential Information includes: (a) the development and operation of Employer’s medical practices, including information
relating to budgeting, staffing needs, marketing, research, hospital relationships, equipment capabilities, and other information concerning such facilities and operations and specifically including the procedures and business plans developed by
Employer for use at the hospitals where Employer conducts its business; (b) contractual arrangements between the Employer and insurers or managed care associations or other payors; (c) the databases of Employer; (d) the clinical and
research protocols of Employer, including coding guidelines; (e) the referral sources of Employer; (f) other confidential information of Employer that is not generally known to the public that gives Employer the opportunity to obtain an
advantage over competitors who do not know or use it, including the names, addresses, telephone numbers or special needs of any of its patients, its patient lists, its marketing methods and related data, lists or other written records used in
Employer’s business, compensation paid to employees and other terms of employment, accounting ledgers and financial statements, contracts and licenses, business systems, business plan and projections, and computer programs. The parties agree
that, as between them, this Confidential Information constitutes important, material, and confidential trade secrets that affect the successful conduct of Employer’s business and its goodwill. Employer acknowledges that the Confidential
Information specifically enumerated above is special and unique information and is not information that would be considered a part of the general knowledge and skill Employee has or might otherwise obtain. 

Notwithstanding the foregoing, Confidential Information shall not include any information that (i) was known by Employee from a
third party source before disclosure by or on behalf of Employer, (ii) becomes available to Employee from a source other than Employer that is not, to Employee’s knowledge, bound by a duty of confidentiality to Employer, (iii) becomes
generally available or known in the industry other than as a result of its disclosure by Employee, or (iv) has been independently developed by Employee and may be disclosed by Employee without breach of this Agreement, provided, in each case,
that the Employee shall bear the burden of demonstrating that the information falls under one of the above-described exceptions. 
 Employee agrees that the terms of this Agreement shall be deemed Confidential Information for purposes of this Section. Employee shall keep the terms of this Agreement strictly confidential and will not,
without the prior written consent of Employer, disclose the details of this Agreement to any third party in any manner whatsoever in whole or in part, with the exception of Employee’s representatives (such as tax advisors and attorneys) who
need to know such information. 
 Employee agrees that Employee will not at any time, whether during or subsequent to the term
of Employee’s employment with Employer, in any fashion, form or manner, unless specifically consented to in writing by Employer, either directly or indirectly, use or divulge, disclose, or communicate to any person, firm or corporation, in any
manner whatsoever, any Confidential Information of any kind, nature, or description, subject to applicable law. The parties agree that any breach by Employee of any term of this Section is a material breach of this Agreement and shall constitute
“cause” for the termination of Employee’s employment hereunder. In the event that Employee is ordered to disclose any Confidential Information, whether in a legal or a regulatory proceeding or otherwise, Employee shall provide
Employer with prompt written notice of such request or order so that Employer may seek to prevent disclosure or, if that cannot be achieved, the entry of a protective order or other appropriate protective device or procedure in order to assure, to

  
 15 

 
the extent practicable, compliance with the provisions of this Agreement. In the case of any disclosure required by law, Employee shall disclose only that portion of the Confidential Information
that Employee is ordered to disclose in a legally binding subpoena, demand or similar order issued pursuant to a legal or regulatory proceeding. 
 All Confidential Information, and all equipment, notebooks, documents, memoranda, reports, files, samples, books, correspondence, lists, other written and graphic records, in any media (including
electronic or video) containing Confidential Information or relating to the business of Employer, which Employee shall prepare, use, construct, observe, possess, or control shall be and remain Employer’s sole property (collectively
“Employer Property”). Upon termination or expiration of this Agreement, or earlier upon Employer’s request, Employee shall promptly deliver to Employer all Employer Property, retaining none. 

8.5.    Ownership of Work Product. Employee agrees and acknowledges that (i) all copyrights, patents,
trade secrets, trademarks, service marks, or other intellectual property or proprietary rights associated with any ideas, concepts, techniques, inventions, processes, or works of authorship developed or created by Employee during the course of
performing work for Employer and any other work product conceived, created, designed, developed or contributed by Employee during the term of this Agreement that relates in any way to Employer’s Business (collectively, the “Work
Product”), shall belong exclusively to Employer and shall, to the extent possible, be considered a work made for hire within the meaning of Title 17 of the United States Code. To the extent the Work Product may not be considered a work made for
hire owned exclusively by Employer, Employee hereby assigns to Employer all right, title, and interest worldwide in and to such Work Product at the time of its creation, without any requirement of further consideration. Upon request of Employer,
Employee shall take such further actions and execute such further documents as Employer may deem necessary or desirable to further the purposes of this Agreement, including without limitation separate assignments of all right, title, and interest in
and to all rights of copyright and all right, title, and interest in and to any inventions or patents and any reissues or extensions which may be granted therefore, and in and to any improvements, additions to, or modifications thereto, which
Employee may acquire by invention or otherwise, the same to be held and enjoyed by Employer for its own use and benefit, and for the use and benefit of Employer’s successors and assigns, as fully and as entirely as the same might be held by
Employee had this assignment not been made. 
 8.6.    Clearance Procedure for Proprietary Rights Not
Claimed by Employer. In the event that Employee wishes to create or develop, other than on Employer’s time or using Employer’s resources, anything that may be considered Work Product but to which Employee believes Employee
should be entitled to the personal benefit of, Employee agrees to follow the clearance procedure set forth in this Section. Before beginning any such work, Employee agrees to give Employer advance written notice and provide Employer with a
sufficiently detailed written description of the work under consideration for Employer to make a determination regarding the work. Unless otherwise agreed in a writing signed by Employer prior to receipt, Employer shall have no obligation of
confidentiality with respect to such request or description. Employer will determine in its sole discretion, within thirty (30) days after Employee has fully disclosed such plans to Employer, whether rights in such work will be claimed by
Employer. If Employer determines that it does not claim rights in such work, Employer agrees to so notify Employee in writing and 

  
 16 

 
Employee may retain ownership of the work to the extent that such work has been expressly disclosed to Employer. If Employer fails to so notify Employee within such thirty (30) day period,
then Employer shall be deemed to have agreed that such work is not considered Work Product for purposes of this Agreement. Employee agrees to submit for further review any significant improvement, modification, or adaptation that could reasonably be
related to Employer’s Business so that it can be determined whether the improvement, modification, or adaptation relates to the business or interests of Employer. Clearance under this procedure does not relieve Employee of the restrictive
covenants set forth in this Section 8. 
 8.7.
    Non-Disparagement. For a period of ten (10) years after the termination of this Agreement, Employee will not, directly or indirectly, as an individual or on behalf of a
firm, corporation, partnership or other legal entity, make any disparaging or negative comment to any other person or entity regarding Employer or any of its affiliates, agents, attorneys, employees, officers and directors, Employee’s work
conditions or circumstances surrounding Employee’s separation from Employer or otherwise impugn or criticize the name or reputation of Employer, its affiliates, agents, attorneys, employees, officers or directors, orally or in writing.

 8.8.    Review by Employee. Employee has carefully read and considered the terms and provisions
of this Section 8, and having done so, agrees that the restrictions set forth in this Section 8 are fair and reasonably required for the protection of the interests of Employer. In the event that any term or
provision set forth in this Section 8 shall be held to be invalid or unenforceable by a court of competent jurisdiction, the parties hereto agree that such invalid or unenforceable term(s) or provision(s) may be severed from this Agreement
without, in any manner, affecting the remaining portions hereof. Without limiting other possible remedies available to Employer, Employee agrees that injunctive or other equitable relief will be available to enforce the covenants set forth in this
Section, such relief to be without the necessity of posting a bond. In the event that, notwithstanding the foregoing, any part of the covenants set forth in this Section shall be held to be invalid, overbroad, or unenforceable by an arbitration
panel or a court of competent jurisdiction, the parties hereto agree that such invalid, overbroad, or unenforceable provision(s) may be modified or severed from this Agreement without, in any manner, affecting the remaining portions of this
Section 8 (all of which shall remain in full force and effect). In the event that any provision of this Section 8 related to time period or areas of restriction shall be declared by an arbitration panel or a court of competent jurisdiction
to exceed the maximum time period, area or activities such arbitration panel or court deems reasonable and enforceable, said time period or areas of restriction shall be deemed modified to the minimum extent necessary to make the geographic or
temporal restrictions or activities reasonable and enforceable. 
 8.9.    Survival. The provisions
of this Section 8 shall survive the termination of this Agreement and Employee’s employment with Employer. The provisions of this Section 8 shall apply during the time Employee is receiving Disability payments from Employer as
a result of a termination of this Agreement pursuant to Section 4.2 hereof. In the event of a breach of this Section 8 by Employee, Employer retains the right to terminate any continuing payments to Employee provided for in
Section 5 of this Agreement. The provisions of this Section 8 are expressly intended to benefit and be enforceable by other affiliated entities of Employer, who are express third party beneficiaries hereof. Employee shall not assist others
in engaging in any of the activities described in the foregoing restrictive covenants. 

  
 17 

 9.    Arbitration. Any controversy or claim arising out of
or relating to this Agreement, or any alleged breach hereof shall be finally determined by binding arbitration before a three member panel, consisting of one member selected by each party hereto, with the third member selected by the first two
arbitrators. Each party hereto shall bear the costs of its own nominee, and shall share equally the cost of the third arbitrator and the parties agree that the costs of arbitration shall not be subject to reapportionment by the arbitration panel.
The arbitration proceedings shall be held in Sunrise, Florida, unless otherwise mutually agreed by the parties, and shall be conducted in accordance with the American Arbitration Association National Rules for the Resolution of Employment Disputes
then in effect. Judgment on the award rendered by the arbitration panel may be entered and enforced by any court having jurisdiction thereof. Notwithstanding anything herein to the contrary, if the Employer shall require immediate injunctive relief,
then the Employer shall be entitled to seek such relief in any court having jurisdiction, and if the Employer elects to do so, the Employee hereby consents to the jurisdiction of the state and federal courts sitting in the State of Florida and to
the applicable service of process. Employee hereby waives and agrees not to assert, to the fullest extent permitted by applicable law, any claim that (i) Employee is not subject to the jurisdiction of such courts, (ii) Employee is immune
from any legal process issued by such courts and (iii) any litigation or other proceeding commenced in such courts is brought in an inconvenient forum. Any such arbitration shall be treated as confidential by all parties thereto, except as
otherwise provided by law or as otherwise necessary to enforce any judgment or order issued by the arbitrators. 

10.    Governing Law. This Agreement shall be governed by and construed in accordance with the laws of
the State of Florida without regard to its conflict of laws principles to the extent that such principles would require the application of laws other than the laws of the State of Florida. 

11.    Notices. Any notice required or permitted to be given under this Agreement shall be in writing
and shall be deemed to have been given when delivered by hand or when deposited in the United States mail by registered or certified mail, return receipt requested, postage prepaid, addressed as follows: 

 

			
	If to Employer:	  	If to Employee:
		
	Mednax Services, Inc.	  	David A. Clark
	1301 Concord Terrace	  	c/o Mednax Services, Inc.
	Sunrise, FL 33323	  	1301 Concord Terrace
	Attention: General Counsel	  	Sunrise, FL 33323

 or to such other addresses as either party hereto may from time to time give notice of to the other in the aforesaid
manner. 
 12.    Benefits: Binding Effect. This Agreement shall be for the benefit of and
binding upon the parties hereto and their respective heirs, personal representatives, legal representatives, successors and, where applicable, assigns.    Notwithstanding the foregoing, Employee may not assign the rights or
benefits hereunder without the prior written consent of Employer. 

  
 18 

 13.    Severability. The invalidity of any one or more of
the words, phrases, sentences, clauses or sections contained in this Agreement shall not affect the enforceability of the remaining portions of this Agreement or any part thereof, all of which are inserted conditionally on their being valid in law,
and, in the event that any one or more of the words, phrases, sentences, clauses or sections contained in this Agreement shall be declared invalid, this Agreement shall be construed as if such invalid word or words, phrase or phrases, sentence or
sentences, clause or clauses, or section or sections had not been inserted. If such invalidity is caused by length of time or size of area, or both, the otherwise invalid provision will be considered to be reduced to a period or area, which would
cure such invalidity. 
 14.    Waivers. The waiver by either party hereto of a breach or
violation of any term or provision of this Agreement shall not operate nor be construed as a waiver of any subsequent breach or violation. 
 15.    Damages. Nothing contained herein shall be construed to prevent Employer or Employee from seeking and recovering from the other damages sustained by either or both
of them as a result of a breach of any term or provision of this Agreement. In the event that either party hereto brings suit for the collection of any damages resulting from, or the injunction of any action constituting, a breach of any of the
terms or provisions of this Agreement, then the party found to be at fault shall pay all reasonable court costs and attorneys’ fees of the other, whether such costs and fees are incurred in a court of original jurisdiction or one or more courts
of appellate jurisdiction. 
 16.    No Third Party Beneficiary. Except as provided in
Section 8.9, nothing expressed or implied in this Agreement is intended, or shall be construed, to confer upon or give any person (other than the parties hereto and, in the case of Employee, Employee’s heirs, personal representative(s)
and/or legal representative) any rights or remedies under or by reason of this Agreement. No agreements or representations, oral or otherwise, express or implied, have been made by either party with respect to the subject matter of this Agreement
which agreements or representations are not set forth expressly in this Agreement, and this Agreement supersedes any other employment agreement between Employer and Employee. 
 17.    Assignment. This Agreement may be assigned by Employer upon notice to Employee. 
 The remainder of this page has been left blank intentionally. 

  
 19 

 IN WITNESS WHEREOF, the undersigned have executed this Agreement this 12th day of
February, 2018, effective as of the Effective Date. 
  

									
	EMPLOYER:	 		 	EMPLOYEE:
				
	MEDNAX SERVICES, INC.	 		 		 	
					
	By:	 	 /s/ Manuel Kadre
	 	        	 	By:	 	 /s/ David A. Clark

		 	Manuel Kadre	 		 		 	David A. Clark
		 	Chairman, Compensation Committee	 		 		 	

  
 20 

 EXHIBIT A 
 BUSINESS OF EMPLOYER 
 As of the date hereof, Employer, directly or through
its affiliates, provides professional medical services and all aspects of practice management services in medical practice areas that include, but are not limited to, the following (collectively referred to herein as “Employer’s
Business”): 
 (1) Neonatology, including hospital well baby care; 
 (2) Maternal-Fetal Medicine, including general obstetrics services; 
 (3) Pediatric Cardiology;

 (4) Pediatric Intensive Care, including Pediatric Hospitalist Care; 
 (5) Newborn hearing screening services; 
 (6) Pediatric Surgery; 

(7) Pediatric Emergency Medicine; 
 (8)
Anesthesiology, critical care medicine and pain management; and 
 (9) Radiology and Teleradiology. 

References to Employer’s Business in this Agreement shall include such other medical service lines, practice management services and
other businesses in which Employer is engaged during the Employment Period; provided, that to be considered a part of Employer’s Business, Employer must have engaged in such other service line, practice management service or other
business at least six (6) months prior to the termination date of this Agreement. For purposes of this Exhibit A, businesses of Employer shall include the businesses conducted by Employer’s subsidiaries, entities under common control and
affiliates as defined under Rule 144 of the Securities Act of 1933, as amended. Such affiliates shall include the professional corporations and associations whose operating results are consolidated with Employer for financial reporting purposes.

 Notwithstanding the foregoing, Employer acknowledges and agrees to the following exceptions and clarifications regarding the
scope of Employer’s Business. 
 A.    Hospital Services. Employer and Employee acknowledge
that, as of the date hereof, Employer does not currently operate hospitals, hospital systems or universities. Nevertheless, the businesses of hospitals, hospital systems and universities would be the same as Employer’s Business where such
hospitals, hospital systems or universities provide or contract with others to provide some or all of the medical services included in Employer’s Business. Therefore, the parties desire to clarify their intent with respect to the limitations on
Employee’s ability to work for or contract with others to provide services for a hospital, hospital system or university during the Employment Period and during the Restricted Period. Section 8.1 shall not be deemed to restrict
Employee’s ability to work for a hospital, hospital system or university if the hospital, hospital system or university does not provide any of the medical services included in Employer’s Business. Furthermore, even if a hospital, hospital
system or university provides medical services that are included in Employer’s Business, Employee may work for such hospital, hospital system or university if Employee has no direct supervisory responsibility for or involvement in the
hospital’s, 

  
 21 

 
hospital system’s or university’s medical services that are Employer’s Business. Finally, Employer agrees that Employee may hold direct supervisory responsibility for or be
involved in the medical services of a hospital, hospital system or university that are included in Employer’s Business so long as such hospital, hospital system or university is located at least ten (10) miles from a medical practice owned
or operated by Employer or its affiliate. Subject to paragraph B below, the provisions of this paragraph shall not apply to the extent that, after the date hereof, Employer enters into the business of operating a hospital or hospital system.

 B.    De Minimus Exception. Employer agrees that a medical service line (other than those listed
in items 1 through 9 above), practice management service or other business in which Employer is engaged shall not be considered to be a part of Employer’s Business if such medical service line, practice management service or other business
constitutes less than Fifteen Million Dollars ($15,000,000) of Employer’s annual revenues. 

C.    Certain Ownership Interests. It shall not be deemed to be a violation of Section 8.1 for
Employee to: (i) own, directly or indirectly, one percent (1%) or less of a publicly-traded entity; or (ii) own, directly or indirectly, less than five percent (5%) of a privately-held business or company, if Employee is at all times a
passive investor with no board representation, management authority or other special rights to control operations of such business or company.  

  
 22 

 EXHIBIT B 
 COMPENSATION 
 Performance Bonus: Up to One Hundred Percent (100%) of
Employee’s Base Salary 
 Equity Compensation: Employee shall be eligible for equity compensation as approved by the Compensation
Committee of the Board of Directors. 

  
 23 

 EXHIBIT C 
 FORM OF RELEASE 
 GENERAL RELEASE OF CLAIMS 

1.                    
(“Employee”), for himself and his family, heirs, executors, administrators, legal representatives and their respective successors and assigns, in exchange for the consideration received pursuant to
Section 5.[    ] of the Employment Agreement to which this release is attached as Exhibit C (the “Employment Agreement”), does hereby release and forever discharge
                     (“Employer”), its subsidiaries, affiliated companies, successors and assigns, and its current or former
directors, officers, employees, shareholders or agents in such capacities (collectively with Employer, the “Released Parties”) from any and all actions, causes of action, suits, controversies, claims and demands whatsoever, for or
by reason of any matter, cause or thing whatsoever, whether known or unknown including, but not limited to, all claims under any applicable laws arising under or in connection with Employee’s employment or termination thereof, whether for
discrimination, harassment, retaliation, tort, breach of express or implied employment contract, wrongful discharge, intentional infliction of emotional distress, or defamation or injuries incurred on the job or incurred as a result of loss of
employment. Employee acknowledges that Employer encouraged him to consult with an attorney of his choosing, and through this General Release of Claims encourages Employee to consult with his attorney with respect to possible claims under the Age
Discrimination in Employment Act (“ADEA”) and that he understands that the ADEA is a Federal statute that, among other things, prohibits discrimination on the basis of age in employment and employee benefits and benefit plans.
Without limiting the generality of the release provided above, Employee expressly waives any and all claims under ADEA that he may have as of the date hereof. Employee further understands that by signing this General Release of Claims he is in fact
waiving, releasing and forever giving up any claim under the ADEA as well as all other laws within the scope of this paragraph 1 that may have existed on or prior to the date hereof. Notwithstanding anything in this paragraph 1 to the contrary, this
General Release of Claims shall not apply to (i) any actions to enforce rights to receive any payments or benefits which may be due Employee pursuant to Section 5.[    ] of the Employment Agreement, or under any of
Employer’s employee benefit plans, (ii) any rights or claims that may arise as a result of events occurring after the date this General Release of Claims is executed, (iii) any indemnification rights Employee may have as a former
officer or director of Employer or its subsidiaries or affiliated companies, (iv) any claims for benefits under any directors’ and officers’ liability policy maintained by Employer or its subsidiaries or affiliated companies in
accordance with the terms of such policy, and (v) any rights as a holder of equity securities of Employer. 

2.    Employee represents that he has not filed against the Released Parties any complaints, charges, or lawsuits
arising out of his employment, or any other matter arising on or prior to the date of this General Release of Claims, and covenants and agrees that he will never individually or with any person file, or commence the filing of, any charges, lawsuits,
complaints or proceedings with any governmental agency, or against the Released Parties with respect to any of the matters released by Employee pursuant to paragraph 1 hereof (a “Proceeding”). 

  
 24 

 3.    Notwithstanding anything in this Agreement to the contrary, nothing in
this Agreement or any other agreement between Employer and Employee shall prevent Employee from filing a charge, sharing information and communicating in good faith, without prior notice to the Company, with any federal government agency having
jurisdiction over the Company or its operations, and cooperating in any investigation by any such federal government agency; However, to the maximum extent permitted by law, Employee agrees that if such an administrative claim is made, Employee
shall not be entitled to recover any individual monetary relief or other individual remedies. 
 4.    Employee hereby
acknowledges that Employer has informed him that he has up to twenty-one (21) days to sign this General Release of Claims and he may knowingly and voluntarily waive that
twenty-one (21) day period by signing this General Release of Claims earlier. Employee also understands that he shall have seven (7) days following the date on which he signs this General Release of
Claims within which to revoke it by providing a written notice of his revocation to Employer. 
 5.    Employee
acknowledges that this General Release of Claims will be governed by and construed and enforced in accordance with the internal laws of the State of Florida applicable to contracts made and to be performed entirely within such State. 

6.    Employee acknowledges that he has read this General Release of Claims, that he has been advised that he should
consult with an attorney before he executes this general release of claims, and that he understands all of its terms and executes it voluntarily and with full knowledge of its significance and the consequences thereof. 

7.    This General Release of Claims shall take effect on the eighth day following Employee’s execution of this
General Release of Claims unless Employee’s written revocation is delivered to Employer within seven (7) days after such execution. 
  

	
	  

	
	                            , 20    

  
 25Exhibit

SOURCE CODE LICENSE AGREEMENT

This Source Code License Agreement (this “Agreement”) is entered into as of October 2, 2017 (the “Effective Date”) by and between Escalon Medical Corp., a Pennsylvania corporation, with offices at 435 Devon Park Drive, Suite 100, Wayne, PA 19087 (“Escalon”), and Modernizing Medicine, Inc., a Delaware corporation, with offices at 3600 FAU Blvd., Suite 202, Boca Raton, Florida 33431 (“MMI”). 

RECITALS

WHEREAS, Escalon desires to grant to MMI, and MMI desires to receive from Escalon, a license to the source code of Escalon’s proprietary image management software, in accordance with the terms and conditions of this Agreement. 

NOW, THEREFORE, in consideration of the foregoing and the mutual covenants contained herein, the parties agree as follows:

AGREEMENT

		
	1.
	DEFINITIONS.

1.1.    “Affiliate” of a party means any Person that controls, is controlled by, or is under common control with such party, now or in the future, for so long as such control exists, where “control” means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through ownership of voting securities or other interests, by contract or otherwise.
1.2.    “Axis Business” means Escalon’s and its Affiliates’ AXIS image management business.
1.3.    “Confidentiality Agreement” means that certain Mutual Confidentiality Agreement dated August 19, 2015 between Escalon and MMI. 
1.4.    “Escalon Software” means all of the Software for Escalon’s (or its Affiliates’) proprietary image management Software product, more fully described in Exhibit A, as it exists as of the Effective Date (including without limitation all server-side and client-side Software, associated desktop Software and mobile applications, and any Software used to integrate the foregoing Software with imaging devices, electronic health records, and other third party Software or devices) for all currently supported platforms, as more fully described in Exhibit A, and any accompanying documentation. Escalon Software also includes any Updates required to be delivered pursuant to Section 3.2. 
1.5.    “Government Authority” means any: (i) nation, state, commonwealth, province, territory, county, municipality, district or other domestic or international jurisdiction of any nature; (ii) federal, state, local, municipal, foreign or other government; or (iii) governmental or quasi-governmental authority of any nature (including, without limitation, the U.S. Food and Drug Administration, the Department of Health and Human Services, the Federal Trade Commission and any other governmental division, department, agency, branch, commission, accreditation or certification authority, instrumentality, official, organization, unit, body or Person and any court or other tribunal).
1.6.    “Intellectual Property Rights” means all current and future worldwide patents and other patent rights, utility models, copyrights, mask work rights, trade secrets, and all other intellectual property rights, including without limitation all applications and registrations with respect thereto.
1.7.    “Licensed Source Code” means the human-readable source code version of the Escalon Software, and all applicable documentation and instructions for configuring and compiling the foregoing to generate and make available the Escalon Software on all currently supported platforms. 
1.8.    “MMI Solutions” means any and all of MMI’s and its Subsidiaries’ current and future products and services, howsoever designated (including private-labeled versions thereof), including without limitation the solution currently marketed under the “EMA” brand, and any related products, services, or Software development toolkits of MMI or its Subsidiaries designed to provide access to or integrate with MMI’s or its Subsidiaries’ products or services, such as mobile applications, desktop Software, and add-ons to third party Software.
1.9.     “Open Source Software” means Software subject to any license that requires, as a condition of use, modification or distribution of any work of authorship, that such work of authorship (i) be made available or distributed in a form other than object code (e.g., source code form); (ii) be made available for license for the purpose of preparing derivative works; (iii) be made available for license under terms that allow any products or services or portions thereof or interfaces therefor to be reverse engineered, reverse assembled or disassembled (other than by operation of law); or (iv) be made available for redistribution for no license fee (including the GNU General Public License, the GNU Library General Public License, the GNU Lesser General Public License, the Affero General Public License, the Mozilla Public License, the Common Development and Distribution License and the Eclipse Public License) meeting the Open Source Definition (as promulgated by the Open Source Initiative) or the Free Software Definition (as promulgated by the Free Software Foundation) or any substantially similar license, including any license approved by the Open Source Initiative and any Creative Commons License, or any other license that is commonly referred to as an “open source”, “free software”, “copyleft”, or “community source code” license.
1.10.    “Person” means an individual, corporation, partnership, limited liability company, association, trust or other entity or organization.
1.11.    “Reseller Agreement” means that certain Axis Image Management Reseller Agreement dated November 7, 2012 between Escalon Medical Corp., d/b/a Sonomed Escalon and Modernizing Medicine, Inc.
1.12.    “Software” means (i) computer programs, including any and all software implementations of algorithms, models and methodologies, whether in source code or object code; (ii) databases and compilations, including any and all data and collections of data, whether machine readable or otherwise; (iii) descriptions, flow-charts and other work product used to design, plan, organize and develop any of the foregoing, screens, user interfaces, report formats, firmware, development tools, templates, menus, buttons and icons; and (iv) all documentation, including user manuals and other training documentation related to any of the foregoing.
1.13.    “Subsidiary” of a party means any Person that is controlled by such party, now or in the future, for so long as such control exists, where “control” means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through ownership of voting securities or other interests, by contract or otherwise.
1.14.    “Third Party Software” means the Software listed on Exhibit B.
2.LICENSE.
2.1.    License. 
		
	2.1.1.
	Grant. Escalon, on behalf of itself and its Affiliates, hereby grants to MMI and its Subsidiaries, a worldwide, non-exclusive, perpetual, irrevocable, non-transferable (except as provided under Section 14.1), license, under Escalon’s and its Affiliates’ Intellectual Property Rights, to use, reproduce, modify, and create derivative works of the Licensed Source Code, and to use, reproduce, distribute, sell, license and otherwise commercially exploit the Licensed Source Code and MMI’s and its Subsidiaries’ modifications and derivative works thereof in executable form (except as provided in Section 2.1.3) solely in conjunction with MMI Solutions (including but not limited to embedded in or as a separate application sold for use with, MMI Solutions, etc.).  

		
	2.1.2.
	Third Party Contractors. MMI and its Subsidiaries may engage third party contractors to exercise the licenses granted in this Section 2.1 on their behalf, and sublicense its rights to the Licensed Source Code to the extent necessary to do so, provided that such contractors who are given access to any Licensed Source Code agree in writing to be bound by terms at least as restrictive and protective with respect to the confidentiality of the Licensed Source Code as those contained in this Agreement.   

		
	2.1.3.
	Escrow. If a customer of MMI requires that MMI place the source code for the MMI Solutions in escrow, MMI may include in the escrowed materials those portions of the Licensed Source Code that are incorporated into or would otherwise be necessary to use and maintain the MMI Solutions, permit release thereof pursuant to the same escrow release conditions that apply to the MMI Solutions source code, and grant the same license or sublicense to such escrowed Licensed Source Code as apply to the licensed MMI Solutions source code, provided that the same confidentiality provisions apply.

2.2.    Restrictions. MMI may not remove or destroy any copyright notices or other proprietary markings on the Licensed Source Code and agrees to ensure that any copy of the Licensed Source Code in its possession or control shall bear Escalon’s copyright, trademark, title, and/or restricted rights notice and other proprietary markings and a notice that the Licensed Source Code is the confidential property of Escalon and that access thereto is strictly limited by the provisions of this Agreement.
2.3.    Ownership. 
		
	2.3.1.
	Licensed Source Code. MMI acknowledges that the Licensed Source Code is the proprietary and confidential information of Escalon and that, except for the rights granted in Section 2.1 above, Escalon retains all right, title, and interest in and to the Licensed Source Code, including without limitation all Intellectual Property Rights therein and thereto. 

		
	2.3.2.
	Modifications and Derivatives Generally. Except as specifically set forth in Section 2.3.3 below, each party retains all Intellectual Property Rights to modifications, derivative works, additions, and extensions to the Licensed Source Code created by or for such party (in the case of MMI, subject to Escalon’s underlying rights in the Licensed Source Code) and neither party has any obligation to provide any such modifications, derivative works, additions, and extensions to the other party except as set forth in Section 3.1 or 3.2. 

		
	2.3.3.
	Modifications and Derivatives Made by Designated Employees. Any Software developed by Escalon in providing Support Services under Section 3.1 will be deemed to be included within Escalon Software. 

2.4.    Third Party Software. Escalon shall provide such cooperation as requested by MMI in order for MMI to obtain such rights to the Third Party Software listed on Exhibit B as deemed appropriate by MMI. 
2.5.    Delivery and Validation of Source Code. Promptly following the Effective Date, Escalon will electronically transmit a complete copy of the Licensed Source Code in its current format to a secure cloud repository to which Escalon initially will have sole access. Promptly following the Effective Date, and provided that Escalon has provided to MMI a complete list in writing of all required development tools and development environment (collectively, “System Requirements”), MMI shall provide a workstation or virtual cloud hosted machine to Escalon that meets the System Requirements (the “Workstation”). Escalon will confirm that it is able to configure and/or compile the Licensed Source Code on the Workstation, in accordance with the written instructions and tools specified by Escalon (the “Instructions”), to create a fully-functioning executable version of the Escalon Software that conforms in all material respects to all documentation applicable to such Escalon Software and shall demonstrate to MMI that such version has been created through such process (“Validation”). If, after up to ten (10) business days after MMI provides the Workstation to Escalon (the “Validation Period”), MMI is unable to confirm Validation of the Licensed Source Code, MMI shall inform Escalon of the deficiency and the Validation Period shall be extended for an additional ten (10) business days, during which Escalon shall have the opportunity to modify the Licensed Source Code and/or its specified Instructions so that MMI is able to confirm Validation of the Licensed Source Code. If Escalon is unable or unwilling to provide a version of the Licensed Source Code with respect to which MMI can confirm Validation prior to the expiration of the Validation Period as so extended, then MMI may, in its sole discretion: (i) extend the Validation Period for an additional reasonable period of time, allowing Escalon to further attempt to provide a version of the Licensed Source Code with respect to which MMI can confirm Validation; (ii) conditionally accept the Licensed Source Code and agree with Escalon on a remediation plan pursuant to which Escalon shall provide a version of the Licensed Source Code that can be Validated; or (iii) terminate this Agreement upon written notice to Escalon without any financial liability or obligation on the part of MMI other than to comply with the requirements of Section 7 of this Agreement with respect to the Licensed Source Code and the Confidentiality Agreement to the extent applicable. If MMI elects option (i) or (ii) and Escalon thereafter fails to correct such deficiency after using the procedures set forth above, MMI may thereafter exercise any of options (i) through (iii). Promptly upon payment of License Fee as provided in Section 4 of this Agreement, Escalon will return the Workstation to MMI, deliver the Instructions and all other documentation applicable to the Licensed Source Code to MMI and provide administrative controls for secure cloud repository for the Licensed Source Code (MMI shall initially access the Licensed Source Code from a location in the State of Florida). 
2.6.    Further Assurances. At any time, or from time to time, on and after the date of this Agreement, Escalon will at the request of MMI (i) deliver to MMI such records, data or other documents consistent with the provisions of this Agreement, (ii) execute, and deliver or cause to be delivered, all assignments, consents, documents or further instruments of license, and (iii) take or cause to be taken all such other actions, as MMI may reasonably deem necessary or desirable in order for MMI to obtain the full benefits of this Agreement and the transactions contemplated hereby.
		
	3.
	SUPPORT SERVICES.

3.1.    Escalon Support. During the three (3) month period after the Effective Date commencing no later than five (5) days after the Effective Date, Escalon will cause mutually agreed-upon employees of Escalon (“Designated Employees) to provide up to one hundred  (100) hours (exclusive of travel time) (the “Free Hours”) of assistance replicating the foregoing Validation throughout the rest of MMI’s design environment, implementation, support and training services, including but not limited to Software architecture, Software compilation, device integration, Software usage, etc. to MMI (the “Support Services”) as reasonably requested by MMI at no additional charge, and thereafter Escalon will provide additional Support Services as reasonably requested by MMI at the rates set forth in Section 4.2. Such Designated Employees will provide Support Services onsite at MMI’s facilities at MMI’s reasonable request.  
		
	3.1.1.
	Relationship with Designated Employees.  At all relevant times while providing the Support Services under this Section 3.1, the Designated Employees shall be employees of Escalon and not employees of MMI.   Nothing in this Agreement shall be deemed to create an employee-employer relationship between MMI and the Designated Employees.  The Designated Employees shall not represent themselves as employees of MMI nor make contractual obligations between MMI and any third party. Escalon understands that MMI is not required to provide the Designated Employees with workers’ compensation.  Escalon acknowledges and understands that Escalon is solely responsible for the Designated Employees’ salary/wages, benefits, workers’ compensation coverage and the employer withholding of federal, state and local income tax, social security, unemployment and disability taxes, and all other applicable charges required by statute, law or ordinance.   MMI shall bear the reasonable costs and travel expenses associated with Designated Employees’ travel as set forth in Section 4.2.

		
	3.1.2.
	Placement Requirements.  Escalon agrees that it will have a completed Form I-9 as required by U.S. Citizenship and Immigration Services on file prior to any Designated Employees being placed at MMI.

		
	3.1.3.
	Removal of Designated Employee(s).  If any Designated Employee fails to perform as provided herein or otherwise violates MMI workplace policies and procedures, MMI may provide written notification to Escalon of the request to remove the Designated Employee from MMI.  Escalon shall remove the Designated Employee immediately and replace the Designated Employee within a commercially reasonable amount of time, not to exceed five (5) business days.   

		
	3.1.4.
	Policies.  The supervision of the Designated Employees on the premises of MMI is the responsibility of MMI.  All Designated Employees shall observe MMI’s workplace policies and procedures and not create any disturbances.  All Designated Employees shall perform the duties as agreed upon by MMI and Escalon.  Upon MMI’s request, Escalon shall obtain the written consent of each of the Designated Employees to adhere to MMI’s Confidential Information, Invention Assignment and Arbitration Agreement (“CIIAAA”) as well as all other MMI workplace policies and procedures.  

		
	3.1.5.
	Representations and Warranties of Escalon.  Escalon represents and warrants as follows:  (a) to the best of Escalon’s knowledge, the Designated Employees have the ability, knowledge, and expertise to adequately perform the services under this Agreement and that the Designated Employees will perform the services in a professional manner and in accordance with the highest industry standards; (b) all services performed by Escalon and Designated Employees in connection with this Agreement shall be performed in compliance with all applicable federal, state and local laws, rules and regulations; (c) all Designated Employees are employees of Escalon, and Escalon shall provide Designated Employees with workers' compensation benefits, unemployment insurance, tax withholding, FICA, or other contributions and benefits on behalf of or for the benefit of the Designated Employees in compliance with all applicable federal, state and local laws, rules and regulations, including but limited to, vacation and holiday pay, if any; and (d) Escalon is an equal opportunity employer and hires and employs all qualified employees regardless of their sex, race, religion, creed, color, national origin, ancestry, physical disability, mental disability, medical condition, marital status, sexual orientation, age or any other basis prohibited by federal, state or applicable local law or ordinance.

		
	3.1.6.
	Indemnity.   Escalon shall indemnify, defend and hold harmless MMI, its stockholders, Affiliates, officers, directors, employees and agents from and against any and all losses, damages, claims, liabilities, judgments, actions, settlements, lawsuits, costs (including, without limitation, reasonable attorneys’ fees and costs and expenses of legal actions) and expenses resulting from or arising out of (i) any breach or reasonably anticipated breach of the CIIAAA by any Designated Employee; (ii) any negligence or intentional misconduct of any Designated Employee or Escalon; or (iii) any matters related to the employment of any Designated Employee.

3.2.    Updates. For a period of two (2) years following the Effective Date, Escalon shall provide to MMI all error corrections and bug fixes to the Licensed Source Code for the Escalon Software developed by or for Escalon or its Affiliates (collectively, “Updates”). Updates will be delivered electronically to MMI.
3.3.    Third Party Software; Open Source Software. Escalon will notify MMI, prior to delivery, of any third party Software in Updates, and any third party Software used in the development of Updates, that is not otherwise listed in Exhibit B as of the Effective Date, and the parties will execute an amendment to Exhibit B and such additional third party Software will be deemed to be Third Party Software under this Agreement. Escalon will notify MMI, prior to delivery, or any Open Source Software that is embedded in or combined with Updates that is not listed in Exhibit C as of the Effective Date, and the parties will execute an amendment to Exhibit C. In any event, with respect to such additional Open Source Software, Escalon will not use it in a way that violates Section 5.2.6 as it applies to Updates.
3.4.    MMI Support. MMI shall be solely responsible for providing support to customers and end users of the MMI Solutions. Escalon shall continue to provide support as required by the Reseller Agreement unless MMI requests Escalon to cease providing such support.  Escalon shall not sell any products or services, which compete with any MMI products or services, to the Persons listed on Exhibit E.
4.CONSIDERATION.
4.1.    License Fee. Subject to MMI’s confirmation of the Validation of the Licensed Source Code, MMI agrees to pay to Escalon a non-refundable license fee of $500,000 within two (2) business days following the end of the Validation Period (as extended) pursuant to Section 2.5, unless otherwise agreed by MMI pursuant to Section 2.5.
4.2.    Support Fees. MMI agrees to pay Escalon for the Support Services at a rate of $150.00 per hour, following the Free Hours. Escalon shall invoice MMI on a monthly basis, and MMI shall pay undisputed amounts within thirty (30) days of receipt of Escalon’s invoice therefor. MMI shall bear the reasonable costs and travel expenses associated with Designated Employees’ travel to provide Support Services onsite at MMI’s facilities when requested by MMI. Escalon shall maintain all books and records relating to Escalon’s provision of Support Services hereunder for a period of no less than three (3) years, and MMI shall have the right, upon reasonable notice, to inspect such books and records and all other documents and materials in Escalon’s possession or control which relate to such services to confirm the accuracy of Escalon’s invoices.  
4.3.    Taxes. The fees payable hereunder include, and MMI shall have no additional obligation to pay, any sales, use, excise, value-added or similar taxes that may be applicable. If MMI has the legal obligation to withhold or collect such taxes, the appropriate amount will be deducted from the license fee. MMI will cooperate with Escalon and take all actions reasonably requested by Escalon in order to secure a reduction or elimination of any withholding taxes pursuant to applicable law.
5.REPRESENTATIONS AND WARRANTIES. 
5.1.    Mutual. Each party represents and warrants that (i) it has the right to enter into this Agreement; (ii) all necessary corporate action has been taken to duly and validly authorize the execution and delivery of this Agreement and to perform its obligations hereunder; (iii) this Agreement is the valid and legally binding obligation of such party in accordance with its terms, subject to bankruptcy, reorganization, insolvency, moratorium and similar laws and to general principles of equity which are within the discretion of courts of applicable jurisdiction. 
5.2.    Escalon. Escalon represents and warrants to MMI that: 
		
	5.2.1.
	as of the Effective Date, no claim, lien, or action exists or is threatened against Escalon that would interfere with MMI’s rights under this Agreement; 

		
	5.2.2.
	the Licensed Source Code does not infringe any Intellectual Property Rights of any third party, and no third party has made any claims to that effect (including invitations to license patents that may be applicable to the Escalon Software); 

		
	5.2.3.
	Escalon or an Affiliate of Escalon is the owner of the Licensed Source Code and all Intellectual Property Rights therein and thereto; the Licensed Source Code has been created by Escalon’s or its Affiliates’ employees, agents, and consultants who have validly assigned all Intellectual Property Rights therein and thereto to Escalon or an Affiliate; and Escalon Holdings, Inc. is an Affiliate of Escalon Medical Corp; 

		
	5.2.4.
	Escalon has all rights necessary in order to grant the rights and licenses granted to MMI in this Agreement and make the assignments to MMI made in this Agreement, on behalf of itself and its Affiliates and Escalon and its Affiliates have not granted any rights inconsistent with the rights granted to MMI under this Agreement;

		
	5.2.5.
	Exhibit B contains a complete and accurate list of all third party Software that is (i) incorporated in or embedded in the Licensed Source Code, or required to be incorporated in or embedded in the Licensed Source Code in order for it to function, or (ii) used by Escalon to design or develop the Licensed Source Code. Except for the Third Party Software described in Exhibit B, the use of the Licensed Software by MMI as contemplated herein will not depend on the acquisition of rights to Software or any Intellectual Property Rights from any third party;

		
	5.2.6.
	Exhibit C contains a complete and accurate list of all Open Source Software included in, incorporated or embedded in, linked to, combined or distributed with, the Escalon Software. No Open Source Software has been included, incorporated or embedded in, linked to, combined or distributed with any Licensed Source Code, in each case, in a manner that obligates MMI to (i) distribute or disclose in source code form any Licensed Source Code or portion thereof; (ii) license any Licensed Source Code or portion thereof for the purpose of preparing derivative works; (iii) license any Licensed Source Code or portion thereof under terms that would allow such Licensed Source Code or portion thereof to be reverse engineered, reverse assembled, or disassembled (other than by operation of law); or (iv) license or otherwise make available on a royalty free basis any Licensed Source Code or portion thereof;

		
	5.2.7.
	Escalon has taken reasonable and appropriate steps to maintain the confidentiality of all Licensed Source Code. Escalon has not disclosed the Licensed Source Code to any third party other than its employees and contractors in the ordinary course of business pursuant to agreements containing confidentiality, non-disclosure and non-use provisions. To the knowledge of Escalon, no third party has infringed or misappropriated any of the Licensed Source Code or Escalon’s Intellectual Property Rights therein or thereto; and 

		
	5.2.8.
	The Licensed Source Code delivered hereunder includes all documentation and comments necessary for a person reasonably skilled in the art to re-create the Escalon Software.

5.3.    Warranty Disclaimer. EXCEPT AS EXPRESSLY PROVIDED IN THIS SECTION 5, NEITHER PARTY MAKES ANY WARRANTY OR CONDITION OF ANY KIND, WHETHER EXPRESS, IMPLIED, OR STATUTORY, UNDER THIS AGREEMENT OR WITH RESPECT TO THE SUBJECT MATTER HEREOF. TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, EACH PARTY AND ITS SUBSIDIARIES, AFFILIATES, LICENSORS AND LICENSEES SPECIFICALLY DISCLAIMS ALL WARRANTIES OF ANY KIND, INCLUDING BUT NOT LIMITED TO (i) ANY IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE; AND (ii) ANY WARRANTIES ARISING OUT OF COURSE OF DEALING, USAGE, OR TRADE.
		
	6.
	LIMITATION OF LIABILITY.

EXCEPT FOR ESCALON’S OBLIGATIONS UNDER SECTION 8, IN NO EVENT WILL EITHER PARTY BE LIABLE TO THE OTHER PARTY OR ANY OTHER PERSON OR ENTITY WITH RESPECT TO ANY SUBJECT MATTER OF THIS AGREEMENT, UNDER ANY CONTRACT, NEGLIGENCE, STRICT LIABILITY OR OTHER LEGAL OR EQUITABLE THEORY, FOR ANY INDIRECT, INCIDENTAL, SPECIAL OR CONSEQUENTIAL DAMAGES.
		
	7.
	CONFIDENTIALITY.

7.1.    Confidential Information. The parties acknowledge and agree that information which one party (the “Discloser”) discloses to the other party (the “Recipient”) in connection with this Agreement in a tangible form and which is marked “Confidential” or “Proprietary” (or with a similar legend), or that is disclosed orally and confirmed in writing as confidential within a reasonable time (not to exceed thirty (30) days from the date of initial disclosure), constitutes the proprietary and confidential information of the Discloser (“Confidential Information”). Even if not so marked, the parties agree that the Licensed Source Code and any related documentation or information shall be “Confidential Information” of Escalon hereunder. 
7.2.    Use and Disclosure. Recipient agrees to keep Confidential Information of the Discloser confidential, not to use Confidential Information except to the extent required to exercise its rights or perform its obligations under this Agreement, and not to disclose Confidential Information unless expressly permitted under this Agreement. Recipient shall take commercially reasonable measures to maintain and hold the Confidential Information in the strictest confidence and to prevent the unauthorized disclosure and use of the Confidential Information. Notwithstanding the foregoing, MMI may disclose the Licensed Source Code, pursuant to confidentiality obligations no less protective than those contained in this Agreement, to third parties (e.g. Black Duck Software) as may be necessary in connection with the performance of due diligence regarding MMI’s business or assets. 
7.3.    Exceptions. The foregoing restrictions will not apply to information that Recipient can demonstrate: (i) was known to Recipient at the time of disclosure to Recipient by Discloser (free of any obligation of confidentiality to Discloser or any party acting on behalf of Discloser) as shown by the files of Recipient in existence at the time of disclosure; (ii) is, at the time of disclosure, in or thereafter becomes part of, generally known to the public through no wrongful act of Recipient; (iii) has been rightfully received from a third party having the lawful right to disclose the same without continuing obligation to Discloser; (iv) has been approved for release by written authorization of Discloser; or (v) has been independently developed by Recipient without any use of Confidential Information, provided that Recipient can demonstrate such independent development by competent evidence. Should Recipient be faced with legal action or a compulsory requirement under government regulations to disclose Confidential Information received hereunder, Recipient shall promptly notify Discloser, and, upon the request and expense of Discloser, shall cooperate with Discloser in contesting such disclosure or in seeking an appropriate protective order or other similar protection. Except in connection with failure to discharge responsibilities set forth in this Section 7, Recipient shall not be liable in damages for any disclosures of such Confidential Information received hereunder pursuant to judicial action or compulsory government regulations or for inadvertent disclosure thereof where the required degree of care has been exercised, provided that promptly upon discovery of such inadvertent disclosure Recipient shall have endeavored to correct the effects thereof and to prevent any further inadvertent disclosure using the same degree of effort Recipient would use to correct the effects of disclosure and prevent further disclosure of its own most highly confidential information. 
7.4.    Agreement Terms. Each party agrees that the terms and conditions, but not the existence, of this Agreement shall be treated as the other’s Confidential Information and that no reference to the terms and conditions of this Agreement or to activities pertaining thereto can be made in any manner without the prior written consent of the other party; provided, however, that each party may disclose the terms and conditions of this Agreement: (i) as required by any court or other Government Authority; (ii) as otherwise required by law; (iii) to legal counsel of the parties; (iv) in connection with the requirements of a public offering or securities filing; (v) in confidence, to accountants, banks, and financing sources and their advisors; (vi) in confidence, in connection with the enforcement of this Agreement or rights under this Agreement; or (vii) in confidence, in connection with a merger or acquisition or proposed merger or acquisition, or the like; provided further that the disclosing party shall, if permitted by applicable law, give the other party prior written notice of any such disclosures under (i), (ii), or (iv) above, and in all cases shall exercise reasonable efforts to preserve the confidentiality of this Agreement, including by cooperating with the other party to obtain an appropriate protective order or other reliable assurance that confidential treatment will be afforded to the Agreement.  
7.5.    Licensed Source Code. Escalon agrees to take reasonable and appropriate steps to maintain the confidentiality of all Licensed Source Code, and not to disclose the Licensed Source Code to any third party other than its employees and contractors in the ordinary course of business pursuant to agreements containing confidentiality, non-disclosure and non-use provisions.
		
	8.
	INDEMNIFICATION.

 Escalon will, at its own expense, indemnify, defend, and hold harmless MMI and its Subsidiaries, directors, managers, officers, equity holders, employees, representatives, agents, successors and assigns against all losses, damages, claims, obligations, settlements, judgments, causes of action, costs, and expenses (including reasonable attorneys’ fees) arising from any and all third party claims alleging that the Licensed Source Code or the MMI Solutions on account of their incorporation of the Licensed Source Code, infringe or misappropriate any third party Intellectual Property Rights or other proprietary rights. MMI shall notify Escalon in writing within thirty (30) days of notification to MMI of the claim, provided that failure to provide such notification shall not relieve Escalon of any of its indemnification obligations except to the limited extent that the rights of Escalon are prejudiced by such delay. Escalon shall have sole control of the defense and all related settlement negotiations, provided that: (i) MMI will have the right to participate in the defense of a claim with counsel of its choice at its expense and (ii) Escalon will not, without the prior written consent of MMI, settle, compromise, or consent to the entry of any judgment that imposes any obligation upon MMI that Escalon does not fully discharge, or admit any liability of MMI. MMI shall provide Escalon with reasonable assistance, information, and authority necessary to perform Escalon’s obligations under this Section 8, at Escalon’s expense, provided that Escalon will not be responsible for any costs or expenses incurred by MMI without Escalon’s written consent. Notwithstanding the foregoing, Escalon shall have no liability if the alleged infringement is attributable to: (a) modification of the Licensed Source Code by MMI or its employees, contractors, or agents (other than by Escalon); or (b) the combination of the Licensed Source Code with Software, hardware or other items not supplied by Escalon for use with the Licensed Source Code, where the infringement would not be present absent such modification or combination. If the Licensed Source Code is held, or believed by Escalon, to infringe any third party Intellectual Property Rights, Escalon shall have the option, at its expense, to (a) modify the Licensed Source Code to be non-infringing; or (b) obtain for MMI a license to continue exercising the license and rights granted under this Agreement with respect to the Licensed Source Code; or if the parties agree that it is not commercially reasonable to perform either (a) or (b) and continued use of the Licensed Source Code is likely to create continuing material liability for MMI for which Escalon would have to indemnify MMI under this Section 8, then either party may (c) terminate the license for the infringing Licensed Source Code and Escalon shall refund to MMI an amount equal to the depreciated license fee paid by MMI (calculated on a straight line basis over a five (5) year life). If Escalon elects to take step (a), (b), or (c), it will consult with MMI to agree upon a process that will minimize impact on MMI. 
		
	9.
	TERM AND TERMINATION.

9.1.    Term. This Agreement shall continue in full force and effect unless and until terminated as provided under this Agreement. 
9.2.    Termination for Breach. Either party may terminate this Agreement immediately upon written notice for the material breach of the other party, which material breach is incurable or has remained uncured for a period of thirty (30) days from the date of delivery of written notice of such breach to the breaching party. Notwithstanding the foregoing, the license granted in Section 2.1 is irrevocable and shall survive any termination of this Agreement pursuant to this Section 9.2; provided that nothing herein prevents Escalon from seeking damages for unauthorized use of the Licensed Source Code or any failure by MMI to pay Escalon fees due to Escalon under Section 4 or injunctive relief to stop or prevent unauthorized use of the Licensed Source Code (but not, for the avoidance of doubt, the proper exercise of the license). 
9.3.    Return of Materials. Promptly following termination of this Agreement, each party shall return to the other party or destroy, at the other party’s option, all copies of the other party’s Confidential Information then in its possession or control and erase any such copies from computer memory and, upon the other party’s request, certify in writing any such destruction and erasure; provided, however, that MMI may retain such copies of the Licensed Source Code and any related documentation as are necessary to support MMI’s continued use of such materials pursuant to the surviving license under Section 2.1. 
9.4.    Survival. The parties’ rights and obligations under Sections 1, 2.1, 2.2, 2.3, 2.4, 2.6, 3.1.6, 4.3, 5, 6, 7, 8, 9.4, 9.5, 12, 13 and 14 shall survive termination of this Agreement.
9.5.    No Waiver. The failure of either party to enforce any provision of this Agreement shall not be deemed a waiver of such provision. 
		
	10.
	DOWNSTREAM BUSINESS ASSOCIATE AGREEMENT.

Escalon shall execute MMI’s form of Downstream Business Associate Agreement, attached hereto as Exhibit D, on the date hereof.
		
	11.
	TRADEMARKS AND PUBLICITY.

Neither party may use any of the other party’s trademarks, service marks, trade names, or logos in any products, websites, advertising or promotional materials in connection with this Agreement. Neither party will issue a press release or otherwise announce, disclose or reveal the existence of this Agreement to any third party without the prior written consent of the other party, except as expressly permitted in Section 7.4.
		
	12.
	REGULATORY.

12.1.    Compliance. Escalon shall comply with and give all notices required by laws, ordinances, rules, regulations or lawful orders of any Government Authority bearing on Escalon’s performance of this Agreement, including any applicable Exhibit.
12.2.    Notification. Escalon shall notify MMI if it becomes aware of any communications with, or notices issued by, any Government Authority, that relate to the legal status of the Licensed Source Code or bear on the performance of this Agreement, including any applicable Exhibit. Any such notices shall be provided to MMI in writing within three (3) days of the date on which Escalon becomes aware of the information.
12.3.    Filings. Escalon shall notify MMI of any communications, including written filings, updates, or notices, that Escalon submits to any Government Authority that relate to the legal status of the Licensed Source Code or bear on the performance of this Agreement. Escalon shall notify MMI of such communications within a reasonable period before the submission of such communications, but in no event, shall such notice be provided less than twenty (20) days prior to the submission, unless timing of submission as required by law precludes provision of a twenty (20) day notice, in which case notice shall be provided as soon as practical. Escalon shall use commercially reasonable efforts to cooperate with MMI to respond to any questions, concerns or issues that bear on the performance of this Agreement before the submission.  Upon written request by MMI, Escalon shall disclose to MMI any information that MMI may require to obtain clearance, approval or permission of a Government Authority to distribute, market or use the Escalon Software or MMI Solutions, to the extent that it exists, and nothing herein shall be deemed to limit MMI’s right to disclose such information to applicable Government Authorities in order to obtain clearance, approval or permission of such Government Authority to distribute, market or use the Escalon Software or MMI Solutions.
12.4.    Audit. Escalon’s records, which shall include, but not be limited to, accounting records, time sheets, written policies and procedures, test results, reports, correspondence, memoranda, internal or Government Authority audits and any other communication relating to the performance of this Agreement, shall be open to inspection and subject to audit and/or reproduction, during normal business hours, by MMI or its authorized representatives to the extent necessary to evaluate claims or information submitted by Escalon, as required by Government Authorities, or as desirable for any other valid business purpose subject to commercially reasonable standards.
		
	13.
	RESELLER AGREEMENT.

13.1.    Termination. Notwithstanding any terms of the Reseller Agreement to the contrary, the parties agree that MMI may terminate the Reseller Agreement immediately upon written notice of such termination to Escalon.
13.2.    Clarification. For the avoidance of doubt, the parties acknowledge and agree that MMI shall owe Escalon no obligations with respect to the Licensed Source Code (or any use of the Licensed Source Code) to Escalon or any other Person under the Reseller Agreement and the terms of the Reseller Agreement shall not be applicable to the Licensed Source Code or this Agreement. Without limiting the foregoing, MMI shall have no obligation to pay any fees to Escalon under the Reseller Agreement with respect to MMI’s use of the Licensed Source Code. The parties further agree that Sections 8.1, 8.2, 8.3 and 8.4 of the Reseller Agreement shall not apply to, and Section 7 of this Agreement will apply to: (i) information exchanged in connection with this Agreement and (ii) the Escalon Software and Licensed Source Code and information relating thereto regardless of whether such information or Software is or was disclosed under this Agreement or the Reseller Agreement.
		
	14.
	MISCELLANEOUS.

14.1.    Assignment. This Agreement may not be assigned by either party without the prior written consent of the other party; provided, however, that either party may assign this Agreement to an Affiliate or a third party acquiring all or substantially all of such party’s business or assets to which the subject matter of this Agreement relates. 
14.2.    Export Controls. MMI agrees to comply, with respect to the Licensed Source Code, with all applicable export control laws and regulations, including the Export Administration Regulations (“EAR”) maintained by the United States Department of Commerce. MMI covenants that it shall not, directly or indirectly, sell, export, re-export, transfer, divert, or otherwise dispose of any Software, source code, or technology (including products derived from or based on such technology) received from Escalon under this Agreement to any country (or national thereof) subject to antiterrorism controls or U.S. embargo without obtaining prior authorization from the competent Government Authorities as required by those laws and regulations. 
14.3.    Governing Law; Venue. This Agreement will be governed by and construed in accordance with the laws of the State of Delaware, U.S.A., except that body of Delaware law concerning conflicts of law. The parties agree that the United Nations Convention on Contracts for the International Sale of Goods is specifically excluded from application to this Agreement. All disputes arising under or in connection with this Agreement shall be brought exclusively in the state and federal courts located in the District of Delaware (Wilmington), and each party hereby consents to the personal jurisdiction of such courts with respect to such disputes. 
14.4.    Notices. All notices and other communications required or permitted hereunder shall be in writing and shall be mailed by registered or certified mail, postage prepaid, or otherwise delivered by hand, by messenger, or by telecommunication, addressed to the addresses set forth below or at such other address furnished with a notice in the manner set forth herein.
If to MMI:                        If to Escalon: 

Modernizing Medicine, Inc.                Escalon Medical Corp.
3600 FAU Blvd., Suite 202                435 Devon Park Drive, Suite 100
Boca Raton, Florida 33431                Wayne, Pennsylvania 19087
Attention: General Counsel                Attention: Rich J. DePiano, Jr.
 
With a copy to:                    With a copy to:
    
Wilson, Sonsini, Goodrich & Rosati             Duane Morris, L.P.
650 Page Mill Road                    30 South 17th Street
Palo Alto, California 94304-1050             Philadelphia, PA 19103-4196
Attention: Suzanne Y. Bell, Esq.             Kathleen Shay, Esquire

Such notices shall be deemed to have been served when delivered or, if delivery is not accomplished by reason of some fault of the addressee, when tendered.
14.5.    Independent Contractors. The parties hereto are independent contractors, and this Agreement shall not be construed as creating an agency, partnership or any other form of legal association between the parties.
14.6.    Partial Invalidity. Any term or provision of this Agreement held to be illegal or unenforceable shall, if possible, be interpreted so as to be construed as valid, but in any event the validity or enforceability of the remainder hereof shall not be affected.
14.7.    Complete Understanding. This Agreement , including all Exhibits, constitutes the entire agreement between the parties with respect to the subject matter hereof, and supersedes and replaces all prior or contemporaneous understandings or agreements, written or oral, regarding such subject matter. Without limiting the foregoing, Escalon acknowledges and agrees that MMI has no obligation to enter into any transaction with Escalon not expressly required by this Agreement.  No amendment to or modification of this Agreement will be binding unless in writing and signed by a duly authorized representative of both parties. The parties acknowledge and agree that the Mutual Confidentiality Agreement dated August 19, 2015 between the parties remains in full force and effect (the “Confidentiality Agreement”) provided that the definition of “Confidential Information” in the Confidentiality Agreement shall not be deemed to include the Escalon Software or any information obtained by MMI in connection with the transactions contemplated by this Agreement.

14.8.    Bankruptcy. All rights and licenses granted to MMI hereunder are, for purposes of Section 365(n) of the United States Bankruptcy Code (the “Bankruptcy Code”), licenses of intellectual property within the scope of Section 101 of the Bankruptcy Code. Escalon acknowledges that MMI, as a licensee of such rights and licenses hereunder, will retain and may fully exercise all of its rights and elections under the Bankruptcy Code.

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the Effective Date.

Escalon Medical Corp.            Modernizing Medicine, Inc.
(on behalf of itself and its Affiliates)

By: __Richard J. DePiano, Jr.    ____        By: ______Daniel Cane_________

Name: __________________    ____        Name: __________________    _____            

Title: ______CEO_________    ____        Title: ________CEO____________

Exhibits:

Exhibit A: Escalon Software 

Exhibit B: Third Party Software

Exhibit C: Open Source Software

Exhibit D: Downstream Business Associate Agreement

Exhibit E:  Client List

1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00279-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00279-of-00352.parquet"}]]